Metohexal (Metoprolol Succinate)

Metoprolol succinate blocks β1‑adrenergic receptors primarily in the heart, which reduces the effects of adrenaline and noradrenaline. This leads to a slower heart rate, decreased contractile force, and reduced renin release from the kidneys, collectively lowering blood pressure and myocardial oxygen demand.

The dose of Metohexal is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength, frequency, and titration schedule, which may be adjusted during therapy.

Safety data for metoprolol succinate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Metohexal product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metohexal (metoprolol succinate) is a cardio‑selective β1‑blocker, offering a favorable profile for patients with respiratory conditions compared with non‑selective agents. Its extended‑release formulation provides once‑daily dosing, which can improve adherence relative to short‑acting beta blockers that require multiple daily doses.

Metohexal should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Metohexal is taken orally, usually once daily due to its extended‑release formulation. It should be swallowed whole with a glass of water and not chewed, crushed, or split, unless the prescriber specifically advises otherwise.

Serious risks include severe bradycardia, heart block, profound hypotension, bronchospasm in susceptible individuals, and worsening heart failure. Patients should be monitored for these events, especially during dose initiation or when combined with interacting medications.

Metohexal is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and in patients with uncompensated heart failure or cardiogenic shock.